GSPT1 degraders have emerged as promising candidates fornovel AML therapies, showing efficacy across various genetic backgrounds (33,55).The CD33-targeting antibody-drug conjugate BMS-986497, which delivers the GSPT1degrader SMol006 specifically to CD33-expressing cells, is currently under clinicalinvestigation for relapsed or refractory AML—both as monotherapy and incombination with azacitidine and venetoclax (ClinicalTrilas.gov:NCT06419634). This evidence concerns the gene CD33 and acute myeloid leukemia.